- Home
- URGN vs NYMT Comparison
URGN vs NYMT Comparison
Compare URGN & NYMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- URGN
- NYMT
- Stock Information
- Founded
- URGN 2004
- NYMT 2003
- Country
- URGN United States
- NYMT United States
- Employees
- URGN N/A
- NYMT N/A
- Industry
- URGN Biotechnology: Pharmaceutical Preparations
- NYMT Real Estate Investment Trusts
- Sector
- URGN Health Care
- NYMT Real Estate
- Exchange
- URGN Nasdaq
- NYMT Nasdaq
- Market Cap
- URGN 547.1M
- NYMT 528.1M
- IPO Year
- URGN 2017
- NYMT 2004
- Fundamental
- Price
- URGN $12.84
- NYMT $5.61
- Analyst Decision
- URGN Strong Buy
- NYMT Buy
- Analyst Count
- URGN 5
- NYMT 4
- Target Price
- URGN $44.50
- NYMT $8.00
- AVG Volume (30 Days)
- URGN 764.9K
- NYMT 657.9K
- Earning Date
- URGN 11-12-2024
- NYMT 10-30-2024
- Dividend Yield
- URGN N/A
- NYMT 14.22%
- EPS Growth
- URGN N/A
- NYMT N/A
- EPS
- URGN N/A
- NYMT N/A
- Revenue
- URGN $85,011,000.00
- NYMT $151,991,000.00
- Revenue This Year
- URGN $16.49
- NYMT N/A
- Revenue Next Year
- URGN $57.58
- NYMT $31.44
- P/E Ratio
- URGN N/A
- NYMT N/A
- Revenue Growth
- URGN 17.22
- NYMT 206.18
- 52 Week Low
- URGN $10.60
- NYMT $5.40
- 52 Week High
- URGN $20.70
- NYMT $9.67
- Technical
- Relative Strength Index (RSI)
- URGN 49.60
- NYMT 34.38
- Support Level
- URGN $11.84
- NYMT $5.40
- Resistance Level
- URGN $13.54
- NYMT $6.68
- Average True Range (ATR)
- URGN 0.82
- NYMT 0.14
- MACD
- URGN 0.08
- NYMT -0.03
- Stochastic Oscillator
- URGN 65.88
- NYMT 20.59
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in innovative solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
About NYMT New York Mortgage Trust Inc.
New York Mortgage Trust Inc is a real estate investment trust for federal income tax purposes, in the business of acquiring, investing in, financing and managing mortgage-related and residential housing-related assets. The company's investment portfolio consists of Structured multi-family property investments such as multi-family CMBS an preferred equity in, and mezzanine loans to owners of multi-family properties. Distressed residential assets such as residential mortgage loans sourced from distressed markets and non-Agency RMBS. Second mortgages, Agency RMBS, and certain other mortgage-related and residential housing-related assets.